Investigational Drug Information for MB-102
✉ Email this page to a colleague
What is the development status for investigational drug MB-102?
MB-102 is an investigational drug.
There have been 6 clinical trials for MB-102.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2022.
The most common disease conditions in clinical trials are Renal Insufficiency, Kidney Diseases, and Leukemia, Myeloid. The leading clinical trial sponsors are MediBeacon, Mustang Bio, and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Summary for MB-102
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 30 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 3 (2022-06-01) |
| Vendors | 6 |
Recent Clinical Trials for MB-102
| Title | Sponsor | Phase |
|---|---|---|
| A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants | MediBeacon | Phase 3 |
| A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 |
| Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring | MediBeacon | Phase 3 |
Clinical Trial Summary for MB-102
Top disease conditions for MB-102
Top clinical trial sponsors for MB-102
US Patents for MB-102
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
